IPOs and Secondaries

IPOs and Secondaries Articles

Specialty materials and chemicals provider PQ Group expects to price 29 million shares for an initial public offering valued up to about $767 million.
Roku is set to dominate the stories around the initial public offering calendar during the last week of September.
Data center operator Switch expects to price more than 31 million shares for an initial public offering valued up to about $575 million.
Seven IPOs are scheduled to hit the public markets this week, including video streaming service Roku and specialty chemicals firm PQ Group, both valued at more than $1 billion before their IPOs.
Database platform provider MongoDB has filed with the SEC regarding its initial public offering.
Biopharmaceutical company Zai Lab intends to price its 8 million shares in the range that results in an initial public offering valued up to more than $165 million.
Chinese logistics firm Best entered the market with a bang on Wednesday, the largest IPO by a Chinese firm in the United States in almost a year.
PQ Group expects to price 29 million shares in a range that results in an initial public offering valued up to about $767 million.
Biotech companies may attempt a secondary offering after seeing a run in the share price. So now seems the as good a time as any for MediWound to capitalize in 2017.
Online automotive marketplace operator CarGurus has filed with the SEC regarding its initial public offering.
Deciphera Pharmaceuticals expects to price more than 6 million shares in a range that results in an initial public offering valued up to more than $122 million.
Roku intends to price more than 15 million shares in a range that results in an initial public offering valued up to more than $252 million.
Seven IPOs are scheduled for the week ahead, making it the busiest week in the third quarter for new companies seeking public financing.
Nightstar Therapeutics intends to price more than 5 million shares in a range that results in an initial public offering valued up to more than $92 million.
T2 Biosystems saw its shares drop handily early on Friday after the firm announced that it would be pricing its secondary offering.